Handelsavisen
prelaunch
Companies Healthcare 950160.KQ
95
950160.KQ KOSDAQ Biotechnology & Medical Research

950160.Kq

$109 100,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-432,7 %
ROE
-303,2 %
Net margin
-3 733,3 %
Debt / equity
1,24
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the healthcare diagnostics segment, developing and commercializing diagnostic solutions for disease detection and monitoring.

Business. The company operates in the healthcare diagnostics segment, developing and commercializing diagnostic solutions for disease detection and monitoring.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target170 000,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
170 000,00
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
-303,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 950160.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 950160.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the healthcare diagnostics segment, developing and commercializing diagnostic solutions for disease detection and monitoring.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 1.24, indicating a moderate reliance on debt financing. Its liquidity position is weak, with a current ratio of 0.24, suggesting limited short-term liquidity to cover immediate obligations. The company holds $47.2 million in cash and equivalents, but this is offset by $55.4 million in long-term debt, resulting in a net cash position of -$8.2 million.

    Profitability metrics are severely negative, with a return on equity of -303.22% and a return on assets of -45.83%. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets. The operating loss of $15.7 million and net loss of $135.4 million further underscore the company's financial distress.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits the company's ability to offset losses in one area with gains in another.

    The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year. The absence of positive revenue trends, combined with significant operating and net losses, suggests a challenging outlook for near-term growth. The company's capital expenditures of $82.6 million indicate ongoing investment, but this has not translated into improved financial performance.

    The company faces significant liquidity and dilution risks. The liquidity risk is rated as medium, with a weak current ratio and negative net cash position. The dilution risk is rated as low, but the company's financial position may necessitate future equity issuances to fund operations or reduce debt. No recent dilutive events have been disclosed.

    Recent events include a strong buy recommendation from one analyst, with a mean price target of $170,000. However, the company's financial performance does not currently support this optimistic outlook. No recent filings or transcripts have been disclosed that provide additional insight into the company's strategic direction or financial health.

    Key takeaways
    • The company is experiencing significant financial distress, with large operating and net losses.
    • Liquidity is weak, with a current ratio of 0.24 and a negative net cash position.
    • Profitability metrics are severely negative, indicating poor returns for shareholders and inefficient asset utilization.
    • The company's revenue is concentrated in a single segment, increasing exposure to market-specific risks.
    • Analysts have issued a strong buy recommendation, but the company's financial performance does not currently support this outlook.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $109 100,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $44.7M
    Net cash
    -$8.2M
    Current ratio
    0.2
    Debt / equity
    1.2
    ROA
    -45.8%
    ROE
    -3.0%
    Cash conversion
    12.0%
    CapEx / revenue
    -22.8%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy1
    Buy0
    Hold0
    Sell0
    Strong sell0
    12-month price target$170 000,00 · Median $170 000,00
    Low $170 000,00High $170 000,00
    Operating income · consensus-27,5B USD

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$170 000,00
    Mean$170 000,00
    Median$170 000,00
    High$170 000,00
    Spot$109 100,00
    +55.8 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-432,7 %Below median
    Net Margin-3 733,3 %Bottom quartile
    ROE-303,2 %Bottom quartile
    Capex / Rev-2 277,0 %Bottom quartile
    D/E1,24Bottom quartile
    Cash Conv0,12Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 950160.KQ Market data — financials · 2026-05-27
    • Kolon TissueGene Inc Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    950160.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage